Cargando…

Health care resource utilization and cost for asthma patients regularly treated with oral corticosteroids – a Swedish observational cohort study (PACEHR)

BACKGROUND: Patients with severe uncontrolled asthma may receive oral corticosteroid (OCS) treatment regularly. The present study investigated the health care resource utilization and cost in regularly OCS treated Swedish asthma patients. METHODS: Primary care medical records data were linked to dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Janson, Christer, Lisspers, Karin, Ställberg, Björn, Johansson, Gunnar, Telg, Gunilla, Thuresson, Marcus, Nordahl Christensen, Helene, Larsson, Kjell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122138/
https://www.ncbi.nlm.nih.gov/pubmed/30176850
http://dx.doi.org/10.1186/s12931-018-0855-3
_version_ 1783352591343681536
author Janson, Christer
Lisspers, Karin
Ställberg, Björn
Johansson, Gunnar
Telg, Gunilla
Thuresson, Marcus
Nordahl Christensen, Helene
Larsson, Kjell
author_facet Janson, Christer
Lisspers, Karin
Ställberg, Björn
Johansson, Gunnar
Telg, Gunilla
Thuresson, Marcus
Nordahl Christensen, Helene
Larsson, Kjell
author_sort Janson, Christer
collection PubMed
description BACKGROUND: Patients with severe uncontrolled asthma may receive oral corticosteroid (OCS) treatment regularly. The present study investigated the health care resource utilization and cost in regularly OCS treated Swedish asthma patients. METHODS: Primary care medical records data were linked to data from Swedish national health registries. Patients ≥18 years with a drug claim for obstructive pulmonary diseases during 2007–2009 (index date) and a prior asthma diagnosis, were classified by their OCS claims during the 12-months’ post index period: regular OCS equals ≥5 mg per day; periodic OCS less than 5 mg per day; or non-OCS users. Cost of asthma- and OCS-morbidity-related health care resource utilization were calculated. RESULTS: A total of 15,437 asthma patients (mean age 47.8, female 62.6%), whereof 223 (1.44%) were regular OCS users, 3054 (19.7%) were periodic, and 12,160 (78.7%) were non-OCS users. Regular OCS users were older and more often females, had lower lung function, greater eosinophil count and more co-morbidities at baseline compared with the other groups. Age-adjusted annual total health care cost was three-times greater in the regular OCS group (€5615) compared with the non-OCS users (€1980) and twice as high as in the periodic OCS group (€2948). The major cost driver in the non-OCS and periodic OCS groups were primary care consultations, whereas inpatient costs were the major cost driver in the regular OCS group. The asthma related costs represented 10–12% of the total cost in all three groups. CONCLUSION: In this real-life asthma study in Sweden, the total yearly cost of health care resource utilization for a regular OCS user was three times greater than for a patient with no OCS use, indicating substantial economic and health care burden for asthma patients on regular oral steroid treatment.
format Online
Article
Text
id pubmed-6122138
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-61221382018-09-05 Health care resource utilization and cost for asthma patients regularly treated with oral corticosteroids – a Swedish observational cohort study (PACEHR) Janson, Christer Lisspers, Karin Ställberg, Björn Johansson, Gunnar Telg, Gunilla Thuresson, Marcus Nordahl Christensen, Helene Larsson, Kjell Respir Res Research BACKGROUND: Patients with severe uncontrolled asthma may receive oral corticosteroid (OCS) treatment regularly. The present study investigated the health care resource utilization and cost in regularly OCS treated Swedish asthma patients. METHODS: Primary care medical records data were linked to data from Swedish national health registries. Patients ≥18 years with a drug claim for obstructive pulmonary diseases during 2007–2009 (index date) and a prior asthma diagnosis, were classified by their OCS claims during the 12-months’ post index period: regular OCS equals ≥5 mg per day; periodic OCS less than 5 mg per day; or non-OCS users. Cost of asthma- and OCS-morbidity-related health care resource utilization were calculated. RESULTS: A total of 15,437 asthma patients (mean age 47.8, female 62.6%), whereof 223 (1.44%) were regular OCS users, 3054 (19.7%) were periodic, and 12,160 (78.7%) were non-OCS users. Regular OCS users were older and more often females, had lower lung function, greater eosinophil count and more co-morbidities at baseline compared with the other groups. Age-adjusted annual total health care cost was three-times greater in the regular OCS group (€5615) compared with the non-OCS users (€1980) and twice as high as in the periodic OCS group (€2948). The major cost driver in the non-OCS and periodic OCS groups were primary care consultations, whereas inpatient costs were the major cost driver in the regular OCS group. The asthma related costs represented 10–12% of the total cost in all three groups. CONCLUSION: In this real-life asthma study in Sweden, the total yearly cost of health care resource utilization for a regular OCS user was three times greater than for a patient with no OCS use, indicating substantial economic and health care burden for asthma patients on regular oral steroid treatment. BioMed Central 2018-09-03 2018 /pmc/articles/PMC6122138/ /pubmed/30176850 http://dx.doi.org/10.1186/s12931-018-0855-3 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Janson, Christer
Lisspers, Karin
Ställberg, Björn
Johansson, Gunnar
Telg, Gunilla
Thuresson, Marcus
Nordahl Christensen, Helene
Larsson, Kjell
Health care resource utilization and cost for asthma patients regularly treated with oral corticosteroids – a Swedish observational cohort study (PACEHR)
title Health care resource utilization and cost for asthma patients regularly treated with oral corticosteroids – a Swedish observational cohort study (PACEHR)
title_full Health care resource utilization and cost for asthma patients regularly treated with oral corticosteroids – a Swedish observational cohort study (PACEHR)
title_fullStr Health care resource utilization and cost for asthma patients regularly treated with oral corticosteroids – a Swedish observational cohort study (PACEHR)
title_full_unstemmed Health care resource utilization and cost for asthma patients regularly treated with oral corticosteroids – a Swedish observational cohort study (PACEHR)
title_short Health care resource utilization and cost for asthma patients regularly treated with oral corticosteroids – a Swedish observational cohort study (PACEHR)
title_sort health care resource utilization and cost for asthma patients regularly treated with oral corticosteroids – a swedish observational cohort study (pacehr)
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122138/
https://www.ncbi.nlm.nih.gov/pubmed/30176850
http://dx.doi.org/10.1186/s12931-018-0855-3
work_keys_str_mv AT jansonchrister healthcareresourceutilizationandcostforasthmapatientsregularlytreatedwithoralcorticosteroidsaswedishobservationalcohortstudypacehr
AT lissperskarin healthcareresourceutilizationandcostforasthmapatientsregularlytreatedwithoralcorticosteroidsaswedishobservationalcohortstudypacehr
AT stallbergbjorn healthcareresourceutilizationandcostforasthmapatientsregularlytreatedwithoralcorticosteroidsaswedishobservationalcohortstudypacehr
AT johanssongunnar healthcareresourceutilizationandcostforasthmapatientsregularlytreatedwithoralcorticosteroidsaswedishobservationalcohortstudypacehr
AT telggunilla healthcareresourceutilizationandcostforasthmapatientsregularlytreatedwithoralcorticosteroidsaswedishobservationalcohortstudypacehr
AT thuressonmarcus healthcareresourceutilizationandcostforasthmapatientsregularlytreatedwithoralcorticosteroidsaswedishobservationalcohortstudypacehr
AT nordahlchristensenhelene healthcareresourceutilizationandcostforasthmapatientsregularlytreatedwithoralcorticosteroidsaswedishobservationalcohortstudypacehr
AT larssonkjell healthcareresourceutilizationandcostforasthmapatientsregularlytreatedwithoralcorticosteroidsaswedishobservationalcohortstudypacehr